Irsogladine maleate alters expression of a tight junction protein in portal hypertensive gastropathy. Issue 5 (22nd September 2020)

• Record Type: Journal Article
• Authors: Yokoyama, Keiji; Irie, Makoto; Tsuchiya, Naoaki; Yamauchi, Eri; Kawashima, Motoko; Miyayama, Takashi; Fukuda, Hiromi; Yamauchi, Ryo; Umeda, Kaoru; Takata, Kazuhide; Tanaka, Takashi; Inomata, Shinjiro; Morihara, Daisuke; Takeyama, Yasuaki; Shakado, Satoshi; Sakisaka, Shotaro; Hirai, Fumihito
• Is Part Of: Journal of gastroenterology and hepatology. Volume 36:Issue 5(2021)
• Page Start: 1208
• Page End: 1215
• Publication Date: 2020-09-22
• Subjects: claudin‐3 -- gastric mucosa -- gastrointestinal diseases -- portal hypertension -- tight junctions; Gastroenterology -- Periodicals; Digestive organs -- Diseases -- Periodicals; Liver -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Liver Diseases -- Periodicals; 616.33
• DOI: 10.1111/jgh.15259
• Languages: English
• ISSNs: 0815-9319

Abstract

Abstract: Background and Aim: Portal hypertensive gastropathy (PHG) is characterized by noninflammatory edema and vasodilatation of the lamina propria of the mucosal epithelium. In addition, the alterations of intercellular junction proteins and dilatation of the endothelial gaps have been reported. In this study, we examined whether irsogladine maleate (IM), a gastric mucosal protective agent, has the potential to improve PHG by restoration of tight junctions (TJs). Methods: Twenty‐four patients with PHG were registered and randomly assigned into two groups: 12 patients in the IM‐administration group and 12 patients in the non‐administration group. In the administration group, IM (4 mg/day) was administered orally for 12 weeks. Gastric mucosa with a red color in patients with PHG were obtained endoscopically on the registration day and 12 weeks later. The endoscopic findings were evaluated, an immunohistochemical analysis of claudin‐3 (a TJ protein) expression in gastric mucosal tissues by a laser microscope was performed, and claudin‐3 expression was quantified by western blot analysis. Results: Irsogladine maleate improved the degree of PHG in 2/12 patients endoscopically, in contrast to none of the 12 patients in the non‐administration group. Immunohistochemical analysis showed that expression of claudin‐3 increased in 8/12 patients in the IM‐administration group and 2/12 patients in the non‐administration group ( P = 0.036). Western blot analysis revealed that the increase in claudin‐3 after 12 weeks was significantly higher in the IM‐administration group than in the non‐administration group ( P = 0.010). Conclusions: The present pilot study suggested that IM might improve the gastric mucosa in PHG through restoration of TJ‐protein claudin‐3.